Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Curran Terrie

2. Date of Event Requiring Statement (MM/DD/YYYY) 6/14/2017

3. Issuer Name and Ticker or Trading Symbol

CELGENE CORP /DE/ [CELG]

(Last) (First) (Middle)

86 MORRIS AVENUE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
See remarks /

(Street)

SUMMIT, NJ 07901

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4710	D
Common Stock	599	I	401(k) Plan

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾ ⁽²⁾	5/1/2023	Common Stock	6572	$58.33	D
Stock Option (right to buy)	⁽¹⁾ ⁽²⁾	5/1/2023	Common Stock	3428	$58.33	D
Stock Option (right to buy)	⁽¹⁾ ⁽³⁾	12/2/2023	Common Stock	3750	$81.56	D
Stock Option (right to buy)	⁽¹⁾ ⁽⁴⁾	7/28/2024	Common Stock	6359	$87.64	D
Stock Option (right to buy)	⁽¹⁾ ⁽⁵⁾	7/28/2024	Common Stock	1141	$87.64	D
Stock Option (right to buy)	⁽¹⁾ ⁽⁶⁾	10/27/2024	Common Stock	5000	$103.10	D
Stock Option (right to buy)	⁽¹⁾ ⁽⁷⁾	12/19/2024	Common Stock	7050	$117.18	D
Stock Option (right to buy)	⁽¹⁾ ⁽⁸⁾	2/2/2025	Common Stock	4157	$118.57	D
Stock Option (right to buy)	⁽¹⁾ ⁽⁹⁾	2/2/2025	Common Stock	843	$118.57	D
Stock Option (right to buy)	⁽¹⁾ ⁽¹⁰⁾	5/4/2025	Common Stock	2500	$109.90	D
Stock Option (right to buy)	⁽¹⁾ ⁽¹¹⁾	7/27/2025	Common Stock	2500	$132.56	D
Stock Option (right to buy)	⁽¹⁾ ⁽¹²⁾	11/9/2025	Common Stock	2500	$114.08	D
Stock Option (right to buy)	⁽¹⁾ ⁽¹³⁾	2/1/2026	Common Stock	1875	$100.80	D
Stock Option (right to buy)	⁽¹⁾ ⁽¹⁴⁾	2/1/2026	Common Stock	625	$100.80	D
Stock Option (right to buy)	⁽¹⁾ ⁽¹⁵⁾	5/2/2026	Common Stock	2773	$104.97	D
Stock Option (right to buy)	⁽¹⁾ ⁽¹⁶⁾	5/2/2026	Common Stock	352	$104.97	D
Stock Option (right to buy)	⁽¹⁾ ⁽¹⁷⁾	8/1/2026	Common Stock	3125	$114.69	D
Stock Option (right to buy)	⁽¹⁾ ⁽¹⁸⁾	10/31/2026	Common Stock	6562	$102.18	D
Stock Option (right to buy)	⁽¹⁾ ⁽¹⁹⁾	1/30/2027	Common Stock	5680	$113.18	D
Stock Option (right to buy)	⁽¹⁾ ⁽²⁰⁾	1/30/2027	Common Stock	883	$113.18	D
Stock Option (right to buy)	⁽¹⁾ ⁽²¹⁾	5/1/2027	Common Stock	6776	$124.06	D
Restricted Stock Unit	⁽²²⁾	⁽²²⁾	Common Stock	1500	⁽²³⁾ ⁽²⁴⁾	D
Restricted Stock Unit	⁽²⁵⁾	⁽²⁵⁾	Common Stock	1765	⁽²³⁾ ⁽²⁴⁾	D
Restricted Stock Unit	⁽²⁶⁾	⁽²⁶⁾	Common Stock	2500	⁽²³⁾ ⁽²⁴⁾	D
Restricted Stock Unit	⁽²⁷⁾	⁽²⁷⁾	Common Stock	2500	⁽²³⁾ ⁽²⁴⁾	D
Restricted Stock Unit	⁽²⁸⁾	⁽²⁸⁾	Common Stock	1563	⁽²³⁾ ⁽²⁴⁾	D
Restricted Stock Unit	⁽²⁹⁾	⁽²⁹⁾	Common Stock	3281	⁽²³⁾ ⁽²⁴⁾	D
Restricted Stock Unit	⁽³⁰⁾	⁽³⁰⁾	Common Stock	3426	⁽²³⁾ ⁽²⁴⁾	D

Explanation of Responses:
(1)	The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated as of April 15, 2015)).
(2)	The option is immediately exercisable and is fully vested.
(3)	The option is immediately exercisable and will fully vest on December 2, 2017.
(4)	The option is immediately exercisable and will vest in two annual installments as follows: 2,500 shares on July 28, 2017 and 1,359 shares on July 28, 2018.
(5)	The option is immediately exercisable and will fully vest on July 28, 2018.
(6)	The option is immediately exercisable and will vest in two equal annual installments commencing on October 27, 2017.
(7)	The option is immediately exercisable and will vest in two annual installments as follows: 1,763 shares on December 19, 2017 and 1,763 shares on December 19, 2018.
(8)	The option is immediately exercisable and will vest in two annual installments as follows: 1,250 shares on February 2, 2018 and 407 shares on February 2, 2019.
(9)	The option is immediately exercisable and will fully vest on February 2, 2019.
(10)	The option is immediately exercisable and will vest in two equal annual installments commencing on May 4, 2018.
(11)	The option is immediately exercisable and will vest in three equal annual installments commencing on July 27, 2017.
(12)	The option is immediately exercisable and will vest in three equal annual installments commencing on November 9, 2017.
(13)	The option is immediately exercisable and will vest in two equal annual installments commencing on on February 1, 2018.
(14)	The option is immediately exercisable and will fully vest on February 1, 2020.
(15)	The option is immediately exercisable and will vest in three annual installments as follows: 781 shares on May 2, 2018, 781 shares on May 2, 2019, and 430 shares on May 2, 2020.
(16)	The option is immediately exercisable and will fully vest on May 2, 2020.
(17)	The option is immediately exercisable and will vest in four annual installments as follows: 781 shares on August 1, 2017, 781 shares on August 1, 2018, 781 shares on August 1, 2019, and 782 shares on August 1, 2020.
(18)	The option is immediately exercisable and will vest in four annual installments as follows: 1,640 shares on October 31, 2017; 1,640 shares on October 31, 2018; 1,641 shares on October 31, 2019, and 1,641 shares on October 31, 2020.
(19)	The option is immediately exercisable and will vest in four annual installments as follows: 1,640 shares on January 30, 2018, 1,641 shares on January 30, 2019, 1,641 shares on January 30, 2020, and 758 shares on January 30, 2021.
(20)	The option is immediately exercisable and will fully vest on January 30, 2021.
(21)	The option is immediately exercisable and will vest in four equal annual installments commencing on May 1, 2018.
(22)	The restricted stock units will vest on August 1, 2017. Vested shares will be delivered to the reporting person promptly after the vesting date.
(23)	The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated as of April 15, 2015)).
(24)	Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
(25)	The restricted stock units will vest on December 19, 2017. Vested shares will be delivered to the reporting person on the vesting date.
(26)	The restricted stock units will vest on May 4, 2018. Vested shares will be delivered to the reporting person on the vesting date.
(27)	The restricted stock units will vest on December 16, 2018. Vested shares will be delivered to the reporting person on the vesting date.
(28)	The restricted stock units will vest on May 2, 2019. Vested shares will be delivered to the reporting person on the vesting date.
(29)	The restricted stock units will vest on October 31, 2019. Vested shares will be delivered to the reporting person on the vesting date.
(30)	The restricted stock units will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date.

Remarks:
President Inflammation & Immunology

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Curran Terrie 86 MORRIS AVENUE SUMMIT, NJ 07901			See remarks

Signatures
/s/ Terrie J. Curran		6/23/2017
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.